SCPS News and Press, Scopus BioPharma Inc. From 05/26/21

Gainers: Asensus Surgical ASXC +37%, Nabriva Therapeutics (NBRV) +29%, Kintara Therapeutics KTRA +26%, Owens & Minor (OMI) +21%, Protagenic Therapeutics (PTIX) +10%.Losers: Larimar Therapeutics LRMR -37%, Travere Therapeutics TVTX ...

IAC/InterActiveCorp (IAC) -31%.Novan (NOVN) -18% on announcing 1-for-10 reverse stock split.Petros Pharmaceuticals (PTPI) -18%.Achieve Life Sciences (ACHV) -15% on proposing stock offeringLordstown Motors (RIDE) -13% on Q1 earnings releaseCreative Realities (CREX...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nvidia (NASDAQ: NVDA ) stock is on the rise Monday after the company announced plans for a stock split. Source: JHVEPhoto / Shutterstock.com Here’s everything investors in NVDA stock need to know about...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, investors in  Scopus Biopharma  (NASDAQ: SCPS ) and SCPS stock are seeing incredible gains. This stock has moved more than 115% higher at the time of writing on extremely heavy volume. Source: ...

Gainers: Scopus BioPharma (SCPS) +97%.MMA Capital (MMAC) +58%.Aptorum (APM) +37%.Creative Realities (CREX) +33%.Obalon Therapeutics (OBLN) +30%.Regional Health Properties (RHE) +24%.Taiwan Liposome (TLC) +21%.Virgin Galactic (SPCE) +19%.Verastem (VSTM) +18%.Veritiv (VRTV) +17%.Loser...

Scopus BioPharma Inc. ( NASDAQ: SCPS ) said the U.S. Food and Drug Administration FDA approved its IND (investigational new drug) application on Monday for CpG-STAT3siRNA – its distinctive immuno-oncology RNA therapy that targets multiple types of cancers. Impact on the s...

Biotech Penny Stocks To Watch After Bullish Analyst Ratings This weekend we discussed how analyst ratings could play a role with penny stocks. Also, reports that accompany them shed light on the future outlook and potential catalysts these firms have an interest in. When it comes to fin...

Scopus BioPharma Inc. (NASDAQ: SCPS) has reported approval of an investigational new drug application by the U.S. FDA for CpG-STAT3siRNA, the immune-oncology RNA therapy to treat multiple cancers. Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will be initiated at City...

The FDA has approved Scopus BioPharma's ([[SCPS]] +109.7%) investigational new drug application ((IND)) for CpG-STAT3siRNA, the distinctive immuno-oncology RNA therapy for the treatment of multiple cancers. A Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will be initiated at Cit...

CpG-STAT3siRNA is a Distinctive RNA Therapy and Immunotherapy Developed at City of Hope A Phase 1 Clinical Trial Will be Initiated at City of Hope NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced the ap...